ELMDA-M10 10/500mg Tablet is a scientifically formulated Dapagliflozin + Metformin (ER) combination designed for effective management of type 2 diabetes mellitus (T2DM). For pharmacies, hospitals, clinics, and medicine stores, sourcing high-quality, reliable antidiabetic medications is critical. As a trusted ELMDA-M10 manufacturer in India and ELMDA-M10 provider in India, Wych Elm Laboratories Limited ensures consistent quality, clinical efficacy, and safe supply for institutional and retail buyers.
Why ELMDA-M10 is the Preferred Choice for Healthcare Providers and Pharmacies
1. Clinically Validated Composition
ELMDA-M10 10/500mg Tablet contains:
- Dapagliflozin 10mg – an SGLT2 inhibitor that reduces renal glucose reabsorption and promotes urinary glucose excretion, helping manage hyperglycemia independently of insulin.
- Metformin 500mg (Extended Release) – a first-line oral antidiabetic that reduces hepatic glucose production, improves insulin sensitivity, and delays intestinal glucose absorption.
This combination delivers:
- Effective glycemic control
- Cardiovascular protection
- Renal benefits
- Potential weight management
For medicine stores and hospitals, this makes ELMDA-M10 an ideal inclusion for chronic diabetes management programs.
2. Institutional Advantages
For pharmacies, hospitals, and medicine dealers, ELMDA-M10 provides:
- Bulk supply from a leading Indian manufacturer
- GMP and WHO-compliant production
- High-quality, evidence-based formulation
- Support for institutional orders and compliance documentation
When searching for a trusted ELMDA-M10 provider in India, Wych Elm Laboratories is recognized for reliable delivery, batch consistency, and regulatory adherence, making it the go-to partner for healthcare providers.
Uses of ELMDA-M10 10/500mg Tablet ER
ELMDA-M10 10/500mg Tablet is indicated for:
1. Type 2 Diabetes Mellitus
- Improves glycemic control by combining insulin-independent glucose excretion (dapagliflozin) with hepatic glucose reduction and insulin sensitization (metformin ER).
- Reduces risk of microvascular complications including nephropathy, neuropathy, and retinopathy.
2. Cardiovascular Risk Reduction
- Supports heart health by lowering the risk of heart attack, heart failure, and other cardiovascular events in patients with type 2 diabetes and pre-existing heart disease.
3. Complement to Lifestyle Modifications
- Prescribed alongside dietary management, exercise, and weight reduction, enhancing the overall management of T2DM.
How ELMDA-M10 Works
ELMDA-M10 10/500mg Tablet combines two mechanisms for comprehensive diabetes management:
- Dapagliflozin: Blocks SGLT2 in the renal tubules → increases urinary glucose excretion → reduces blood sugar levels.
- Metformin (ER): Decreases hepatic glucose production → delays intestinal glucose absorption → improves peripheral insulin sensitivity.
Together, these mechanisms provide superior glycemic control, reduce cardiovascular risk, and may help manage overweight or obese diabetic patients.
Dosage & Administration
- Dose: As prescribed by your doctor; typically once daily with food.
- Route: Oral, Extended Release formulation ensures steady blood levels.
- Administration Tips: Swallow whole, do not crush, chew, or break.
Pharmacist Tip: Educate patients on taking ELMDA-M10 at the same time daily and monitoring blood glucose levels regularly for optimal outcomes.
Benefits of ELMDA-M10 Tablet
- Enhanced Glycemic Control: Reduces fasting and postprandial blood glucose levels.
- Cardiovascular Protection: Lowers risk of heart failure and cardiovascular complications.
- Renal Safety: Supports kidney function and reduces the progression of chronic kidney disease.
- Weight Management: Encourages modest weight loss via urinary glucose excretion.
- Dual Mechanism Therapy: Combines dapagliflozin and metformin for synergistic blood sugar reduction.
For healthcare providers, ELMDA-M10 offers versatile treatment options for complex T2DM cases, particularly when monotherapy is insufficient.
Side Effects & Safety
Common Side Effects:
- Nausea, vomiting, diarrhea
- Polyuria (frequent urination)
- Genital fungal infections, urinary tract infections
- Nasopharyngitis (throat/nasal inflammation)
- Flatulence, skin rash, taste changes
- Hypoglycemia (if combined with insulin or sulfonylureas)
Special Precautions:
- Pregnancy & Breastfeeding: Consult doctor; not recommended due to limited safety data.
- Kidney/Liver Disease: Dose adjustment may be necessary.
- Alcohol: Avoid, as it may increase risk of lactic acidosis and hypoglycemia.
Pharmacy Guidance: Emphasize hydration, genital hygiene, and blood glucose monitoring to patients.
Quick Tips for Medicine Dealers & Healthcare Providers
- Educate patients on hydration and UTI prevention.
- Monitor renal function, liver function, and blood sugar.
- Combine with other antidiabetic medications when indicated, with caution.
- Stock sufficient bulk supply to prevent institutional shortages.
- Promote patient adherence by advising consistent timing and lifestyle management.
FAQs for ELMDA-M10 10/500mg Tablet
Q1: What is ELMDA-M10 10/500mg Tablet used for?
A: Manages type 2 diabetes by combining dapagliflozin and metformin ER, improving insulin sensitivity, reducing glucose production, and promoting glucose excretion via urine.
Q2: Who should not take ELMDA-M10?
A: Patients with severe kidney disease, liver disease, diabetic ketoacidosis, or known allergy to dapagliflozin/metformin.
Q3: Can ELMDA-M10 cause low blood sugar?
A: Rarely when used alone, but risk increases if combined with insulin or sulfonylureas. Monitor blood sugar regularly.
Q4: Does ELMDA-M10 cause weight loss?
A: Yes, primarily due to dapagliflozin-induced urinary glucose excretion; weight loss varies individually.
Q5: Can it be taken during pregnancy or breastfeeding?
A: Not recommended due to insufficient safety data; consult a doctor for alternatives.
Q6: How does it reduce cardiovascular risk?
A: By controlling blood sugar, promoting mild diuresis, reducing blood pressure, and improving cardiac workload, ELMDA-M10 reduces risk of heart attack, heart failure, and other cardiovascular events.
Q7: Can it be combined with other antidiabetic drugs?
A: Yes, with medical supervision. Combination therapy may enhance glycemic control while requiring careful monitoring for hypoglycemia.
Why Wych Elm Laboratories is the Top ELMDA-M10 Manufacturer in India
For pharmacies, hospitals, and clinics, sourcing reliable antidiabetic medicines is essential. Wych Elm Laboratories Limited offers:
- GMP-certified, WHO-aligned production
- Consistent batch quality
- Bulk supply options for institutional buyers
- Evidence-based, clinically supported formulations
When searching for the best ELMDA-M10 provider in India, Wych Elm Laboratories stands out as a trusted partner for medicine dealers, clinics, and hospitals, ensuring safety, quality, and timely delivery.
Purchase & Institutional Orders: ELMDA-M10 10/500mg Tablet | Wych Elm Laboratories